维普中文期刊产品整合服务

Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease

查看全文 作　　者：Michael [1]Wagner;Christer GB [2]Peterson;Peter [2]Ridefelt;Per [1]Sangfelt;Marie [1]Carlson 高影响力作者 机构地区：[1]Department of Medical Sciences, Gastroenterology Research Group, University Hospital, SE-751 85 Uppsala, Sweden;[2]Department of Medical Sciences, Clinical Chemistry, University Hospital, SE-751 85 Uppsala, Sweden高影响力机构 出　　处：《World Journal of Gastroenterology》索引2008年第14卷第36期,共6页高影响力期刊 基　　金：Grants from the Medical Faculty, Uppsala University, Uppsala, Sweden 摘　　要：AIM: To evaluate fecal calprotectin (FC) as a surrogate marker of treatment outcome of relapse of inflammatory bowel disease (IBD) and, to compare FC with fecal myeloperoxidase (MPO) and fecal eosinophil protein X (EPX). METHODS: Thirty eight patients with IBD, comprising of 27 with ulcerative colitis (UC) and 11 with Crohn’s disease (CD) were investigated before treatment (inclusion), and after 4 and 8 wk of treatment. Treatment outcomes were evaluated by clinical features of disease activity and endoscopy in UC patients, and disease activity in CD patients. In addition, fecal samples were analyzed for FC by enzyme-linked immunosorbent assay (ELISA), and for MPO and EPX with radioimmunoassay (RIA). RESULTS: At inclusion 37 of 38 (97%) patients had elevated FC levels (> 94.7 μg/g). At the end of the study, 31 of 38 (82%) patients fulfilled predefined criteria of a complete response [UC 21/27 (78%); CD 10/11 (91%)]. Overall, a normalised FC level at the end of the study predicted a complete response in 100% patients, whereas elevated FC level predicted incomplete response in 30%. Normalised MPO or EPX levels predicted a complete response in 100% and90% of the patients, respectively. However, elevated MPO or EPX levels predicted incomplete response in 23% and 22%, respectively. CONCLUSION: A normalised FC level has the potential to be used as a surrogate marker for successful treatment outcome in IBD patients. However, patients with persistent elevation of FC levels need further evaluation. FC and MPO provide superior discrimination than EPX in IBD treatment outcome. 关 键 词：粪便 肠炎 溃疡性结肠炎 克罗恩氏病 髓过氧物酶 嗜曙红细胞蛋白X
相关文献

参考文献(37)

引证文献(10)

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费